financetom
Business
financetom
/
Business
/
Bitcoin Miner Marathon's Shares Tumble After Revenue Unexpectedly Misses Wall Street's Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bitcoin Miner Marathon's Shares Tumble After Revenue Unexpectedly Misses Wall Street's Estimates
Aug 1, 2024 2:56 PM

The shares of bitcoin miner Marathon Digital ( MARA ) fell as much as 8% on Thursday post-market trading after the company's second quarter revenue missed Wall Street's expectations. The shares have recouped some of their losses since then.

Marathon reported revenue of $145.1 million versus an estimate of $157.9 million, according to FactSet data. The company's sales took a hit in the second quarter due to several operational challenges which hindered its ability to mine bitcoin as well as recent halving weighing on the mining sector, Marathon said in its earnings release.

"During the second quarter of 2024, our BTC production was impacted by unexpected equipment failures and transmission line maintenance at the Ellendale site operated by Applied Digital ( APLD ), increased global hash rate, and the April halving event,” said Fred Thiel, the firm's CEO, in a statement.

However, Marathon said that the issues have since been remedied and the company reached an all-time high mining power of 31.5 exahash per second (EH/s) in the second quarter.

The miner also said that its second quarter adjusted EBITDA swung to a loss of $85.1 million from a gain of $35.8 million in the previous year, mainly due to unfavorable fair value adjustments of its digital assets and lower BTC being mined in the quarter.

Despite the challenges, the miner continues to see reaching hashrate of 50 EH/s by the year-end and plans to growth it further next year.

Marathon sold 51% of the bitcoin it mined in the second quarter to fund its operating costs. However, it recently announced that it bought $100 million worth of bitcoin in the open market and re-adopted strategy to fully hold all BTC in its balance sheet. The miner now holds more than 20,000 BTC in its balance sheet.

"During the quarter, we organized the internal structure of the business to better align with our growth opportunities, sharpen our strategic focus, bolster accountability, and accelerate our speed and agility as we scale," said Thiel.

Read more: Bitcoin Miner Marathon Buys $100M BTC, Will Once Again Adopt 'Full HODL' Strategy

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Price: 5.73, Change: -0.05, Percent Change: -0.87 ...
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Friday their marketing authorization applications for HLX14, a denosumab biosimilar, have been validated by the European Medicines Agency. The submissions were based on a phase 3 study comparing HLX14 with denosumab in postmenopausal women with osteoporosis, the companies said. Henlius licensed HLX14 to Organon in 2022...
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) on Friday reported a narrower loss for the first quarter even though the company has not generated revenues from operations and had an accumulated deficit of $45.2 million at the end of March. The company reported a first-quarter net loss of $2.4 million, or $0.03 per share, compared...
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) late Thursday reported that an ongoing phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%. Of 26 patients in all the trial cohorts who have had their first scan while...
Copyright 2023-2025 - www.financetom.com All Rights Reserved